Physician profile
Yixing Jiang
NPI 1720037971
$13,820.11
in general payments reported to CMS, 2019-2025
17 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,997 · 2022: $273 · 2023: $6,818 · 2024: $605 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,698 · Consulting Fee: $2,380 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,698.46 |
| Consulting Fee | $2,380.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Food and Beverage | $672.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,930.19 | 2019 | |
| Exelixis INC. | $4,835.03 | 2019-2024 | Cabometyx |
| Taiho Oncology, INC. | $1,980.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $506.12 | 2023-2024 | Imfinzi, Calquence |
| Novocure Gmbh | $237.57 | 2022-2023 | Optune |
| Intera Oncology, INC | $73.49 | 2025 | Intera |
| Astellas Pharma US INC | $71.62 | 2022 | |
| Novocure INC. | $62.28 | 2022 | |
| Accord Healthcare, INC. | $34.21 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2019 | |
| Pfizer INC. | $25.01 | 2023 | |
| Incyte Corporation | $20.42 | 2025 | Zynyz, Jakafi |
| Amgen INC. | $18.39 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yixing Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.